Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

Introduction Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor s...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Patrick Michl, Peter Schirmacher, Andreas Teufel, Christoph Springfeld, Dirk Jäger, Anastasia Tsakmaklis, Anja Sander, Arne Kandulski, Conrad Rauber, Maria Paula Roberti, Maria JGT Vehreschild, Thomas Ettrich, Leonie Jochheim, Pavlos Missios, Raphael Mohr, Alexander Reichart, Dirk T Waldschmidt, Lukas D Sauer, Michael T Dill
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMJ Publishing Group 2025-09-01
Σειρά:	BMJ Open
Διαθέσιμο Online:	https://bmjopen.bmj.com/content/15/9/e097802.full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!